VEGFA and pancreatic neoplasm: Increased levels of vascular endothelial growth factor (VEGF) expression in tumors has been correlated with increased rates of recurrence and metastasis.[13–15] Bevacizumab, a humanized anti-VEGF monoclonal antibody has been studied extensively for possible use as an anti-angiogenic agent in pancreatic cancers patients.